AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06269029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proprioceptive neuromuscular facilitation
Description: The technique used in this study Proprioceptive neuromuscular facilitation technique of hold and relax stretching for isolated clavicular head of the pectoralis major muscle. The subjects sitting on a chair with back support to keep spine in a neutral position and both their arms are extended and hands are placed behind the occipital region. His both arms will be positioned in glenohumeral horizontal extension, and glenohumeral abduction and external rotation with elbow bent to perform stretch position of pectoral muscle. Then ask him to contract the pectoral muscles .This isometric contraction is held for 6 seconds. The patient then relaxed and passive stretch in the opposite direction . and it was repeated 6 times with rest period 30 seconds. The session will be given every day for one week
Study NCT05300672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fibrinogen infusion
Description: fibrinogen infusion (2 g) in stroke patients with secondary post-rtPA hypofibrinogenemia
Study NCT04905784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Differential learning
Description: The patient will be requested to perform different exercises, each exercise one time a day for 3 days in a row before moving to the next exercise. All patient will be asked to do the exercises in the same sequence.
Study NCT04905784 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual toothbrushing
Description: The patients in this group will be provided with the regular oral health instructions, including the traditional toothbrushing recommendations.
Study NCT06589505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Software as a Medical Device
Description: The subject will undergo treatment using the Software as a Medical Device
Study NCT06317298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib and Everolimus
Description: Fruquintinib and Everolimus
Study NCT05570747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eclipse novel CPAP mask
Description: Participants will follow instructions to set up and put on the Eclipse nasal mask. The Eclipse removes the headgear associated with traditional CPAP masks, offering a small compact design weighing less than an ounce. The Eclipse uses small and lightweight adhesive seals around the nostrils to create an ergonomic design which accommodates the shape of each individual user. It completes a perfect circuit for CPAP therapy to deliver pressure to the airway and stabilize the user's disordered breathing during sleep (apnea and snoring).~Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly.
Study NCT05570747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phillips Respironics Nuance
Description: Participants will follow instructions to set up and put on the Respironics Nuance, traditional nasal mask. Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly.
Study NCT06589505 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Software as a Medical Device
Description: The subject will undergo treatment using the Software as a Medical Device
Study NCT05044104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Consumer-facing wearable smart watch
Description: Wearable watch technology that has the ability to measure heart rate, respiratory rate, single-lead electrocardiography, and blood oxygen saturation.
Study NCT05529355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab plus Endostar and S-1
Description: Immunotherapy combined with chemotherapy and anti VEGFR therapy
Study NCT05529355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envafolimab plus Endostar
Description: Immunotherapy combined with anti VEGFR therapy
Study NCT05529355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envafolimab plus S-1
Description: Immunotherapy combined with chemotherapy
Study NCT06245239 — intervention group
Intervention type: DEVICE
Intervention: perfusion index
Description: measurement of perfusion index
Study NCT05133713 — intervention group
Intervention type: DEVICE
Intervention: Catheter directed therapy
Description: Thrombectomy
Study NCT04634851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual home visits
Description: These participants will have a tailored evaluation of dietary choices based on their home dietary environment (refrigerator, pantry, etc). This will be conducted over video exchange.
Study NCT05054959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: consolidation chemotherapy
Description: 6 cycles CAPOX after chemoradiotherapy
Study NCT05054959 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: induction chemotherapy
Description: 4 cycles CAPOX before and 2 cycles CAPOX after chemoradiotherapy
Study NCT05133713 — intervention group
Intervention type: DRUG
Intervention: Systemic anticoagulation
Description: Conservative therapy
Study NCT06205836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Patients will receive cemiplimab (350 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.
Study NCT06205836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fianlimab
Description: Patients will receive fianlimab (1600 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.
Study NCT05256797 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban
Description: Any rivaroxaban dispensing claim is used as the reference group
Study NCT05256797 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Description: Any apixaban dispensing claim is used as the exposure group
Study NCT04944368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
Description: SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
Study NCT04944368 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: 0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
Study NCT05981937 — intervention group
Intervention type: DRUG
Intervention: ICG solution
Description: ICG-ATT is available at our institute since 2019 using a near-infrared (NIR) light source and special scope and camera equipped with xenon light (CARL STORZ GmbH \& Co. KG, Tuttlingen, Germany); ICG was supplied as a sterile water-soluble lyophilized powder (Diagnostic Green® GmbH). ICG-ATT is routinely used whenever available in daily practice with the following protocol: after the specimen resection the two colonic stumps or colonic and rectal stumps are checked with 5 cc of ICG 25 mg diluted in 10 cc of water sterile solution before fashioned anastomosis. Two laparoscopes with ICG-optic system are nowadays available department and ICG anastomosis control is always performed if ICG device are available (no performed in case of not available ICG instrument for sterilization in case of two consecutive surgery in the same day, concomitant ICG surgery or ICG malfunction).
Study NCT05178329 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifting exercise
Description: Patients are instructed for a light lifting exercise after mastectomy.
Study NCT05178329 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard exercise
Description: Standard exercise program after mastectomy
Study NCT05654688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: graston and muscle energy technique
Description: Graston technique (Gt) is a technique of mobilization of soft tissue using instruments which consider myofascial release instrument that has been reported to relieve pain, improve overall function, and increase range of motion.~Muscle energy technique (MET) is a term composed of various types of active muscular relaxation and stretching procedures. The two cornerstone forms of MET are reciprocal inhibition and post isometric relaxation. In theory, reciprocal inhibition takes advantage of the neurological phenomena of muscular contraction, which results in an inhibitory effect on the antagonistic muscles.
Study NCT04689932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic AVNU
Description: Ferric Pyrophosphate Citrate
Study NCT05433441 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESPark Intervention
Description: The treatment will include 15 sessions (1 session per week). An initial assessment will be carried out during the first session in order to determine the objectives and the personalized follow-up.
Study NCT04996407 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: survival thermal blanket
Description: patients were given a thermal blanket
Study NCT04996407 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: draping fabric
Description: Patients were given a draping fabric
Study NCT05654688 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: graston and muscle energy technique
Description: Graston technique (Gt) is a technique of mobilization of soft tissue using instruments which consider myofascial release instrument that has been reported to relieve pain, improve overall function, and increase range of motion.~Muscle energy technique (MET) is a term composed of various types of active muscular relaxation and stretching procedures. The two cornerstone forms of MET are reciprocal inhibition and post isometric relaxation. In theory, reciprocal inhibition takes advantage of the neurological phenomena of muscular contraction, which results in an inhibitory effect on the antagonistic muscles.
Study NCT05057442 — intervention group
Intervention type: OTHER
Intervention: Proprioception assessment, functionality assessment
Description: Proprioception assessment, functionality assessment
Study NCT05701774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCCR
Description: Once daily oral administration
Study NCT05113615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Bromide
Description: respimat inhaler 2.5mcg/puff
Study NCT05113615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: matching placebo Respimat inhaler
Study NCT05735522 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal magnetic stimulation
Description: Extracorporeal magnetic stimulation is a technique based on Faraday's law of magnetic induction, approved by the United States Food and Drug Administration in 1998, for conservative treatment of urinary incontinence. It generates electrical activity, which induces controlled depolarization of the nerves, resulting in pelvic muscle contraction and sacral S2-S4 roots neuromodulation. The patient seats in the chair fully clothed.
Study NCT05735522 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The same chair as is used in the active group with the magnetic field density at the lower 2% resulting in negligible efficacy.
Study NCT06504433 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Confirmed variant/deletion in either nuclear or mitochondrial genes involved in the mitochondrial respiratory chain
Description: This is a 10-year, longitudinal, non-randomised, retrospective and prospective, observational study that will be used to characterise the natural history of primary mitochondrial disease (MITO) in 400 participants and their asymptomatic family members (with no genetic risk), non-MITO healthy controls (100 participants) and form a biobank that can be used in future research using separate ethics approved protocols to identify biomarkers of disease onset and progression.
Study NCT06489795 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic or robot-assisted radical/simple hysterectomy
Description: In the experimental arm, patients with early-stage cervical cancer will be treated by using laparoscopic or robot-assisted radical, or in the case of SHAPE criteria, simple hysterectomy.
Study NCT06489795 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Abdominal radical/simple hysterectomy
Description: In the control arm, patients with early-stage cervical cancer will be treated by using abdominal radical, or in the case of SHAPE criteria, simple hysterectomy as standard therapy.
Study NCT05297487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: early use of intermittent positive pressure breathing
Description: standard care associated with daily and early use of intermittent positive pressure breathing
Study NCT05081947 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: COMPASS
Description: COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions (LTC) (https://compass-ltc.org/). An example of the patient login page can be viewed here: www.compass-southwark.co.uk. COMPASS aims to support people in managing the challenges of living with a long-term condition. COMPASS is based on research which shows the benefit of combining mental and physical healthcare. The proposed COMPASS program consists of 11 online sessions for patients to work through over approximately 12 weeks. The sessions can be worked through in any order the patient would like. The sessions are split into four quadrants - North, East, South and West - which explore different elements of managing the LTC challenges that were identified from the evidence-based systematic review. Sessions contain information, interactive tasks, goal setting and patient stories.
Study NCT05985278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [ Lu-177]-Catalase
Description: \[ 177Lu\]-Catalase is administered by intratumoral puncture every four weeks, and the specific dose is related to the size of the tumor
Study NCT06422858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab will be administered as a fixed dose of 300 mg via intravenous infusion every three weeks, continuing for up to 12 months or until disease progression, unacceptable toxicity, or withdrawal of consent
Study NCT06422858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-gimeracil-oteracil potassium capsule(S1)
Description: S1 will be administered at a dose of 60 mg/m2 per day, taken orally in two divided doses on day 1 concurrent with radiotherapy, repeated every 28 days; and from day 1 to day 14 of each 21-day cycle, for up to 12 months or until disease progression, unacceptable toxicity, or withdrawal of consent
Study NCT06422858 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be delivered as a total dose of 50.4 Gy in 28 fractions over six weeks using techniques such as IGRT, IMRT, VMAT, or TOMO, targeting the primary tumor and associated lymph nodes
Study NCT06422858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered at a dose of 75 mg/m\^2 on day 1 concurrent with radiotherapy, repeated every 28 days
Study NCT06536205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation
Description: Psychoeducation, psychological difficulties or physical diseases; These are structured educational interventions aimed at teaching people about their illness and their emotional responses to the illness, developing coping skills, ensuring compliance with the illness and cooperation with treatment.
Study NCT04790812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Single, preemptive oral dose 200mg of celecoxib. A cyclooxygenase-2 (COX-2) selective inhibitor for pain management. A COX-2 selective nonsteroidal anti-inflammatory drug (NSAID).
Study NCT06625892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the multidimensional interventions
Description: The study participants will receive cognitive behavior therapy intervention for six weeks, one session per week, 45 minutes each time, and exercise training for twelve weeks, twice sessions per week, 60 minutes each time.
Study NCT06632717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy regimen~• Cisplatin 60mg/m2 on day 2; 5-fluorouracil (5-FU) 500mg/m2 on day 1 - day 3 via the HAIC port, every 3 weeks until progression or intolerable toxicity
Study NCT06632717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Chemotherapy regimen~• Cisplatin 60mg/m2 on day 2; 5-fluorouracil (5-FU) 500mg/m2 on day 1 - day 3 via the HAIC port, every 3 weeks until progression or intolerable toxicity
Study NCT06632717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipiodol embolization
Description: Lipiodol embolization protocol~* Lipiodol embolization will be performed on day 3 after completion of 5-FU infusion, up to 4 cycles. Fixed dose lipiodol of 10mL will be given on day 3 followed by 30mL normal saline flush.~* The administration of lipiodol is mandatory on cycle 1. The administration of lipiodol on cycle 2 to cycle 4 will depend on the discretion of the treating physician and the presence of adverse effects from lipiodol embolization.
Study NCT06633783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.
Study NCT06633783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.
Study NCT04790812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib
Description: Single, preemptive oral dose 200mg of celecoxib. A cyclooxygenase-2 (COX-2) selective inhibitor for pain management. A COX-2 selective nonsteroidal anti-inflammatory drug (NSAID).
Study NCT04790812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Single, preemptive oral dose 1000mg of acetaminophen. An over-the-counter medication for pain management.
Study NCT04790812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A capsule with no active ingredients designed to mimic the appearance of the acetaminophen capsule to ensure blinding of patients and care providers.
Study NCT06106165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-person peer-led faith-based intervention to encourage breast, bowel, and cervical screening uptake among Muslim women
Description: The intervention includes a two-hour workshop, delivered in-person, that aims to improve the uptake of cancer screening among Muslim women.~The workshop consists of four parts:~* A peer-led discussion on barriers and facilitators to breast, cervical and colorectal cancer screening~* A health information session led by a health professional~* Videos of Muslim women talking about their experiences with cancer screening~* A religious perspective on cancer screening led by a female religious scholar
Study NCT06106165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online In-person peer-led faith-based intervention to encourage breast, bowel, and cervical screening uptake among Muslim women
Description: The intervention includes a two-hour workshop, delivered online, that aims to improve the uptake of cancer screening among Muslim women.~The workshop consists of four parts:~* A peer-led discussion on barriers and facilitators to breast, cervical and colorectal cancer screening~* A health information session led by a health professional~* Videos of Muslim women talking about their experiences with cancer screening~* A religious perspective on cancer screening led by a female religious scholar
Study NCT04791241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: check-list including lung ultrasound
Description: The investigator will follow the checklist which includes the collection of anamnestic data and clinical signs, the performance of a pulmonary embolism clinical probability score and a cardiopulmonary ultrasound with count -standardized rendering. After completing this checklist, the investigator will note their diagnosis (list of proposals on the data collection sheet), the treatments started (closed list of therapeutic classes). If he orders other tests, he will write them down and then note the diagnosis made and the treatments prescribed after obtaining the results of these tests.~The therapeutic management of patients compared to the usual care in the respective departments may be modified depending on the results of the cardiopulmonary ultrasound . The emergency physician may initiate therapy before the results of additional examinations that he would have usually performed without cardiopulmonary ultrasound.
Study NCT05487482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ageing Safe from the Risk (ASRi) Model of safety culture
Description: For the intervention groups, planning will be done to provide education and training. Families will be given modules on Safety Culture in the Elderly. Materials provided about the safety of the elderly include changes in the elderly, the concept of safety in the elderly, the type of danger to the elderly, how to prevent harm in the elderly, the first handling in case of accidents, and the role of the family in the efforts of elderly safety. The material will be delivered by experts in elderly health and patient safety (professionals from health centers, social services, and academics). In addition to education and training, families will also receive home visits to check and monitoring the condition of the elderly at home related to adverse events and the home environment. Measuring will be done every 4 weeks by using a monitoring book.